1988
Inception of Ravi Laboratories (RLL)
Founded by Late Mr. K. Tata Rao Garu.
1989
Establishment of the 1st Manufacturing Facility
Launched the first facility dedicated to manufacture Oral Dosage forms (Tablets, Capsules, Liquids).
1999
Transition of Leadership
Mr. K. Anil Kumar succeeded Late Shri K. Tata Rao Garu.
2001
Inception of SAI Parenterals (P) Ltd
Incorporated with Ompro Promoters as Anup Saxena and Swaroop Saxena.
2003
Business Expansion
RLL entered Institutional Domestic Business by participating in Institutional tenders for Govt. & Corporate Hospitals.
2016
Acquisition of SAI Family RLL
Acquired SAI Form and Promoters, Unit 1 & 2 for Injectable preparations.
2017
Modernization of SAI & Commercial Operations
Unit 1 and Unit 2 were modernized and commenced activity in 2017.
2020
Prefilled Technology Introduced
Prefilled Syringe Technology introduced in Unit 2. WHO GMP granted.
2022
SAI Achieved 100cr Mark
Crossed turnover of 100 crore from Unit 1, Unit 2, and RLL.
Acquisition of Riche India
Expanded into regulatory TGA markets (Australia).
2022
Acquisition of Japanese firm “Medichiyaku”
SAI acquired Medichiyaku, accredited at 72 countries, to manufacture Cephalosporins in dry powder and OSD forms.
2023
SAI Crossed 100 crores Turnover Mark
First time crossed ₹100 crores turnover on standalone basis.
2023
Ravi Crossed 50 crores Turnover Mark
Crossed ₹50 crores turnover on standalone basis.
2023
Renewal of Accreditation by TGA Australia
Successfully filed 1st International regulatory renewal audit of TGA Australia at Unit 3.
2023
First Product Dossier filed with TGA Australia
Filed its first R&D center dossier to TGA Australia, out of 11 products are filed this year to TGA Australia.
2023
Commercial Activity Starting from Unit 4
Started the Commercial Injectable Facility at Unit 4 in December 2023.
2023
Setting up R&D facility at Bhopal
Established its first R&D center at Bhopal for new product and molecule development.
2024
RLPL becomes 100% subsidiary
RLPL became a 100% subsidiary of SAI in Feb 2024 through Share Transfer.
2024
RLPL becomes 100% subsidiary
RLPL again confirmed as 100% subsidiary in Feb 2024 through Share Transfer.
